Vilagli Tablet 50 mg

DPP-4 inhibitor for type 2 diabetes in adults, with diet and exercise — alone (if metformin unsuitable) or with metformin, a sulphonylurea, a glitazone or insulin.

Adults: 50 mg twice daily (morning and evening) — or 50 mg once daily in the morning when combined with a sulphonylurea.

• Maximum 100 mg daily.
• Moderate–severe kidney impairment (eGFR < 50): 50 mg once daily.
• With or without food.

• Allergy to vildagliptin
• Liver impairment, including ALT/AST > 3 × upper limit of normal before treatment
• Type 1 diabetes, diabetic ketoacidosis

Common: dizziness, headache, tremor, low blood sugar (with sulphonylureas), nausea, swelling of the hands/feet (with glitazones).

Rare but serious: liver injury/hepatitis, pancreatitis, angioedema (especially with ACE inhibitors), blistering skin reactions (bullous pemphigoid), joint pain.

• Liver function tests before starting, every 3 months in the first year, then periodically; stop if jaundice.
• Stop and seek help for severe persistent abdominal pain.
• Heart failure (NYHA IV): not recommended.

Not recommended in pregnancy (insulin preferred) or while breastfeeding.

• Sulphonylureas, insulin (hypoglycaemia — lower their dose)
• ACE inhibitors (higher angioedema risk)
• Thiazides, corticosteroids (may reduce effect)

Muscle pain, swelling, fever, raised liver enzymes at very high doses. Supportive care.

Store below 30°C, protected from moisture.